Genomics Core

Information

  • Research Project
  • 10237341
  • ApplicationId
    10237341
  • Core Project Number
    P30DK089507
  • Full Project Number
    5P30DK089507-12
  • Serial Number
    089507
  • FOA Number
    RFA-DK-19-003
  • Sub Project Id
    8129
  • Project Start Date
    7/6/2010 - 13 years ago
  • Project End Date
    5/31/2025 - a year from now
  • Program Officer Name
  • Budget Start Date
    6/1/2021 - 2 years ago
  • Budget End Date
    5/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    12
  • Suffix
  • Award Notice Date
    8/25/2021 - 2 years ago

Genomics Core

PROJECT SUMMARY/ABSTRACT The purpose of the Genomics Core is to provide instrumentation, computational infrastructure, technical and analytic expertise, and guidance in order to broadly enable and to enhance the use of genomic analysis in Cystic Fibrosis (CF) research. Among other areas of research focus, the Genomics Core places a special emphasis in understanding host-microbe interactions in individuals with CF. The Aims of the Core are to: 1) Provide sequencing and computational resources to study microbial communities in the CF gut, 2) Provide cutting-edge sequencing and computational resources that advance research on pathogens associated with CF disease states, 3) Provide advanced services to understand gene expression and molecular physiology of human cells that are relevant to CF disease states, and 4) Develop novel technologies for the genome-scale analysis of CF microbiology. These aims will be fulfilled by providing UW CF researchers with consultative, production, and analytical services relevant to the following domains: i. Consultation on genomic methods and experimental design. ii. Data Analysis, Data Management, and Data Sharing Services. iii. Bacterial whole genome sequencing. iv. Metagenomic and 16S rRNA Microbiome data generation and Analysis. v. Transcriptome sequencing (RNA-Seq) and targeted gene expression analysis (qRT-PCR). vi. Gut microbe quantitation by Digital Droplet PCR (dPCR). vii. New sequencing technology innovation. In addition to defining the microbiome of the gut at various timepoints and in various disease states of individuals with CF, the Core will play a primary role in driving projects to define how the microbiomes of the gastrointestinal (GI) and respiratory tracts change across the full lifespan of patients with CF, and to understand how the administration of highly effective CFTR modulators changes the composition and metabolic functions of the microbiome and its interface with host cells.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    P30
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
    192685
  • Indirect Cost Amount
    0
  • Total Cost
  • Sub Project Total Cost
    192685
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIDDK:192685\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    ZDK1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SEATTLE CHILDREN'S HOSPITAL
  • Organization Department
  • Organization DUNS
    048682157
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    981053901
  • Organization District
    UNITED STATES